Zenyaku Kogyo Kabushiki Kaisha

Shinichi Yaguchi

Tetsuo Watanabe

Toshiyuki Matsuno

Seiichiro Kawashima

Yoshio Tsuchida

Masayuki Takahashi

Kenichi Saitoh

Hiroya Sasahara

Kimitomo Yoshioka

Kazuhiko Haruta

Ryogo Yui

Toshiaki Suzuki

Yoshiharu Tanaka

Toshihiko Komatsu

Masanobu Kato

Hideshi Kobayashi

Yuriko Watanabe

Manami Masuda

Soichi Ohta

Hideki Satoh

Hajime Ono

Seiichi Fukuda

Naohito Ogose

Yasuhiro Izumisawa

Tsutomu Nakagane

Tadaaki Sugama

Masahiro Inaba

Masato Kawashima, Legal Representative

Hiroto Kawashima, Legal Representative

Mitsuko Kawashima, Legal Representative

Nobuhiro Ishihara

Tomoyoshi Kayou

Yoshie Minowa

Ichiro Koshimizu

Seiichiro (deceased) Kawashima

Disclosed are: a novel purine derivative, a composition thereof, a method for treating tumor using the purine derivative, and an antitumor agent using the purine derivative. Specifically disclosed is a compound represented by formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, or a prodrug thereof.

Purine derivative and antitumor agent using same

A novel method for immunosuppressive in a mammal suffering from an immune disease, including administering to the mammal a therapeutically effective amount of a heterocyclic compound represented by the general formula (I) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is disclosed. A novel heterocyclic compound represented by the general formula (II) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is also disclosed.

Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient

[Problems] The object is to improve the absorbability of a heterocyclic compound including s-triazine and a pyrimidine derivative in vitro. [Means for Solving Problems] Disclosed is, for example, an amorphous body of a heterocyclic compound as represented by the general formula (I) [wherein each of R's and others is as defined in the description] including s-triazine and a pyrimidine derivative, or a hydrate, a solvate or a pharmaceutically acceptable salt of the heterocyclic compound. Also disclosed is a process for producing the amorphous body. Further disclosed are: a solid dispersion comprising the amorphous body; and a medicinal preparation comprising the solid dispersion.

Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same

Heterocyclic compounds represented by the formula I and anti-malignant-tumor agents containing the heterocyclic compounds as effective components: wherein X represents nitrogen atom or CH; Y represents C-Calkyl; Rrepresents morpholino (which may be substituted with one to four C-Calkyl); and Rand Reach represent hydrogen atom or C-Calkyl.

Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient

The present invention relates to heterocyclic compounds represented by the formula I or pharmaceutically acceptable salts thereof and antitumor agents containing the heterocyclic compounds as effective components: wherein X represents nitrogen atom or CH; Rrepresents CHF(wherein n is 1 or 2), hydroxy C-Calkyl, NHR[wherein Rrepresents hydrogen atom or COR (wherein R represents hydrogen atom, C-Calkyl or C-Calkoxy)]; Rrepresents morpholino (which may be substituted with one to four C-Calkyl), thiomorpholino, piperidino, pyrrolidinyl (which may be substituted with hydroxy C-Calkyl), oxazolidinyl (which may be substituted with one or two C-Calkyl) or tetrahydro-1,4-thiazin-1-oxo-4-yl; Rand Reach represent hydrogen atom or C-Calkyl; and Rrepresents hydrogen atom, amino or hydroxyl.

Heterocyclic compound and antitumor agent containing the same as effective ingredient

The present invention relates to heterocyclic compounds represented by the formula I wherein X represents nitrogen atom or CH; Rrepresents halogen atom or hydroxyl; Rrepresents hydrogen atom, hydroxyl or amino; Rrepresents morpholino (which may be substituted with one or two C&#x2013;Calkyl), pyrrolidinyl (which may be substituted with hydroxy C&#x2013;Calkyl) or NRR[Rrepresents C&#x2013;Calkyl and Rrepresents piperidinyl (which may be substituted with C&#x2013;Calkyl)]; Rand Reach represents hydrogen atom or C&#x2013;Calkyl, with the proviso that Ris hydrogen atom and Ris pyrrolidinyl (which may be substituted with hydroxy C&#x2013;Calkyl) when Ris hydroxyl

Heterocyclic compounds and antitumor drugs containing the same as the active ingredient

The present invention relates to heterocyclic compounds represented by the formula I or pharmaceutically acceptable salts thereof and antitumor agents containing the heterocyclic compounds as effective components: wherein X represents nitrogen atom or CH; Rrepresents CHF(wherein n is 1 or 2), hydroxy C&#x2013;Calkyl, NHR[wherein Rrepresents hydrogen atom or COR (wherein R represents hydrogen atom, C&#x2013;Calkyl or C&#x2013;Calkoxy)]; Rrepresents morpholino (which may be substituted with one to four C&#x2013;Calkyl), thiomorpholino, piperidino, pyrrolidinyl (which may be substituted with hydroxy C&#x2013;Calkyl), oxazolidinyl (which may be substituted with one or two C&#x2013;Calkyl) or tetrahydro-1,4-thiazin-1-oxo-4-yl; Rand Reach represent hydrogen atom or C&#x2013;Calkyl; and Rrepresents hydrogen atom, amino or hydroxyl.

Heterocyclic compound and antitumor agent containing the same as active ingredient

Heterocyclic compounds in which s-triazine or pyrimidine is substituted with benzimidazole and morpholine and which are represented by the Formula I or phermaceutically acceptable acid addition salts thereof:

Heterocyclic compounds and antitumor agent containing the same as active ingredient

S-triazine derivative and remedy for estrogen-dependent disease

Growing community of inventors

Tokyo, Japan

Shinichi Yaguchi